Key Points – Abbott beat expectations in Q2, reporting 4.8% comparable sales growth and adjusted EPS of $1.31.
Management said results showed an acceleration from prior quarters and raised full-year adjusted EPS guidance to $5.45 to $5.60. – Margins improved, with second-quarter adjusted gross margin rising to 58.0% of sales, up 100 basis points year over year
Abbott cited better product mix, the Exact Sciences addition, operational improvements and margin initiatives as key drivers. – Growth was broad in medical devices and diagnostics, while nutrition stayed strong. Medical devices rose 8.5% led by electrophysiology, rhythm management, heart failure and CGM, while diagnostics showed strong core lab and cancer testing but weaker rapid/molecular sales due to lower respiratory virus testing. – Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year comparable sales growth guidance of 6.5% to 7.5% and raised its adjusted EPS guidance range to $5.45 to $5.60.
Chief Financial Officer Phil Boudreau said Abbott expects third-quarter adjusted EPS of $1.38 to $1.46. – AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead? Ford said Abbott entered the second half of the year with “momentum building across the portfolio” and “clear line of sight” to the drivers behind expected sales growth acceleration. He said the company’s focus on gross margin expansion supported the higher earnings outlook.